Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment.

IF 5.5 3区 医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-11-17 DOI:10.1080/14760584.2024.2428243
Charles Reynard, James Campling, Adam L Gordon, George Kassianos, Hui-Hsuan Liu, Alex Richter, Andrew Vyse, Dexter J Wiseman, Hannah Wright, Gillian Ellsbury
{"title":"Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment.","authors":"Charles Reynard, James Campling, Adam L Gordon, George Kassianos, Hui-Hsuan Liu, Alex Richter, Andrew Vyse, Dexter J Wiseman, Hannah Wright, Gillian Ellsbury","doi":"10.1080/14760584.2024.2428243","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Vaccine-preventable respiratory infections (VPRI) including those caused by Streptococcus pneumoniae, influenza, respiratory syncytial virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pose substantial challenges to health and social care systems. In the UK, routine adult respiratory vaccination programs are in place. The objective of this article is to review the current evidence on the impact of four seasonal VPRIs in adults risk group definitions and to explore the strengths and limitations of current recommendations, and to identify evidence gaps for further research.</p><p><strong>Areas covered: </strong>Relevant evidence on UK data from surveillance systems, observational studies and publicly available government documents is collated and reviewed, as well as selected global data.</p><p><strong>Expert opinion: </strong>Disparities exist between adult risk group categories for different respiratory vaccination programs as defined in the current vaccination guidance. The burden of multiple respiratory pathogens signifies importance of routine multi-pathogen testing with the need for a resilient and large-scale national surveillance system. Further understanding of epidemiological trends and disease burden will help guide decision-making and planning of targeted strategies for disease prevention and control. Addressing inequalities in disease burden and vaccine coverage particularly in clinical risk groups, and promoting equitable vaccine access remain a priority.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"1052-1067"},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2428243","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Vaccine-preventable respiratory infections (VPRI) including those caused by Streptococcus pneumoniae, influenza, respiratory syncytial virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pose substantial challenges to health and social care systems. In the UK, routine adult respiratory vaccination programs are in place. The objective of this article is to review the current evidence on the impact of four seasonal VPRIs in adults risk group definitions and to explore the strengths and limitations of current recommendations, and to identify evidence gaps for further research.

Areas covered: Relevant evidence on UK data from surveillance systems, observational studies and publicly available government documents is collated and reviewed, as well as selected global data.

Expert opinion: Disparities exist between adult risk group categories for different respiratory vaccination programs as defined in the current vaccination guidance. The burden of multiple respiratory pathogens signifies importance of routine multi-pathogen testing with the need for a resilient and large-scale national surveillance system. Further understanding of epidemiological trends and disease burden will help guide decision-making and planning of targeted strategies for disease prevention and control. Addressing inequalities in disease burden and vaccine coverage particularly in clinical risk groups, and promoting equitable vaccine access remain a priority.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
疫苗可预防呼吸道感染的成人风险群体:英国环境概述。
导言:疫苗可预防的呼吸道感染(VPRI),包括由肺炎链球菌、流感、呼吸道合胞病毒和严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的呼吸道感染,给医疗和社会保健系统带来了巨大挑战。在英国,常规的成人呼吸道疫苗接种计划已经实施。本文旨在回顾目前有关四种季节性 VPRIs 对成人风险组定义的影响的证据,探讨目前建议的优势和局限性,并找出有待进一步研究的证据差距:专家意见:专家意见:根据现行疫苗接种指南的定义,不同呼吸道疫苗接种计划的成人风险群体类别之间存在差异。多种呼吸道病原体造成的负担表明,常规的多种病原体检测非常重要,需要一个有弹性和大规模的国家监测系统。进一步了解流行病学趋势和疾病负担将有助于指导决策和规划有针对性的疾病防控战略。解决疾病负担和疫苗覆盖率不平等的问题,特别是在临床风险群体中,以及促进疫苗的公平接种仍然是一个优先事项。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Vaccines
Expert Review of Vaccines 医学-免疫学
CiteScore
9.10
自引率
3.20%
发文量
136
审稿时长
4-8 weeks
期刊介绍: Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
期刊最新文献
Adult vaccination in three Eastern Mediterranean countries: current status, challenges and the way forward. Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomized clinical trial. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines. Estimating the time required to reach HPV vaccination targets across Europe. Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1